A panel of U.S. Food and Drug Administration advisers is set to vote Wednesday on whether to recommend approval of Grail Inc.’s Galleri test, a blood-based screening tool designed to detect multiple cancers in apparently healthy individuals through a single blood draw.
The test, which analyzes DNA fragments shed by tumor cells, is intended for people 50 and older and aims to identify up to 50 types of cancer, many of which currently lack routine screening methods. The FDA’s advisory committee will assess whether the proposed benefits of the test outweigh potential risks, including missed diagnoses or false alarms.
The FDA is not required to follow the panel’s recommendation but typically does so. If approved, the test could become eligible for insurance reimbursement, including under Medicare, following recent congressional action. Currently, the test is available to consumers for $949 or more out of pocket.
Key Regulatory Decision Looms
The FDA’s advisory panel, composed of independent experts, will evaluate data presented by Grail, FDA officials, and public testimony before casting its vote. The agency has expedited its review of the Galleri test, marking it as a bellwether for the multi-cancer detection industry.
In pre-meeting documents, FDA staff did not raise major safety concerns but questioned whether the test detects enough early-stage cancers to justify its use for early detection. The panel’s deliberations will focus on the test’s accuracy, clinical utility, and potential harms.
How the Test Works and Its Potential Impact
The Galleri test operates by identifying circulating tumor DNA (ctDNA) in blood samples, a method known as liquid biopsy. Unlike traditional cancer screenings—such as mammograms or colonoscopies—which target single cancers, this approach aims to provide a broader, single-test alternative for early detection.
Grail emphasizes that the test is not intended to replace existing screenings but to complement them. For example, it could be used alongside colonoscopies or mammograms to detect cancers that lack standard screening protocols.
Proponents argue that such technology could significantly improve early diagnosis rates, potentially saving lives by identifying tumors before symptoms appear. The test’s developers claim it can detect cancers at earlier stages, when treatment is more likely to be effective.
Financial and Industry Implications
The financial stakes for approval are substantial. Congress has approved Medicare coverage for multi-cancer detection tests that receive FDA clearance, creating a strong incentive for companies like Grail. The Galleri test is the most advanced in this category, making its outcome a critical test case for the industry.
If approved, the test could expand access to cancer screening, particularly for cancers that currently lack routine detection methods. However, critics warn that false positives—where the test incorrectly indicates cancer—could lead to unnecessary follow-up procedures, increased anxiety, and higher healthcare costs.
What’s Next?
The FDA’s advisory panel will vote Wednesday on whether to recommend approval. The agency will then consider the panel’s advice before making a final decision. If approved, the test could become a standard tool in cancer screening, pending further validation and regulatory steps.
For now, the Galleri test remains available to consumers without FDA approval, though at a high out-of-pocket cost. The outcome of Wednesday’s vote could determine whether it becomes a widely accessible medical tool or remains a niche, unvalidated option.